Nexalin Technology

Nexalin operates at the intersection of medical devices, neuroscience, mental health, and digital care. Its core differentiation is a non-invasive, drug-free neurostimulation approach using proprietary frequency-based waveforms, rather than pharmaceutical treatment or implanted stimulation. The company is extending that hardware proposition through Gen-2 SYNC, Gen-3 HALO, HALO Clarity, and the NeuroCare virtual clinic, which combines treatment delivery, virtual appointments, monitoring, records, and patient-management functions. This creates a broader product model than a standalone stimulation device, although the commercial and regulatory maturity of the platform remains less established than larger neurotechnology and digital-mental-health competitors. The available comparison set does not identify specific peer companies, so relative market share cannot be quantified. Nexalin’s competitive case currently rests on its focus on anxiety, insomnia, depression, traumatic brain injury, and Alzheimer’s-related applications; its reported clinical and neuroimaging studies; and its developing distribution and research relationships, including the University of California, San Diego collaboration and Carmi Masha Technologies agreement in Israel. The principal constraints are a small disclosed workforce of fewer than 10 employees, limited public operating metrics, and an investigational pipeline that still depends on clinical and regulatory execution.

Nexalin’s trajectory shows a transition from a focused neurostimulation-device developer toward a combined medical-device and digital-care platform. The company was founded in 2010, went public on Sep 20, 2022, and recorded three structured funding rounds totaling $10.75 million, including $5.25 million in 2024 and $5 million in 2025 post-IPO equity. Additional financial disclosures describe a $9.6 million initial public offering, creating a funding-history discrepancy that limits confidence in the aggregate total. Product development has broadened from the Nexalin Neurostimulation Device to Gen-2 SYNC, Gen-3 HALO, HALO Clarity, and NeuroCare. The February 2026 NeuroCare launch was a key inflection point because it connected home-based treatment with virtual clinical management and a university research relationship. Clinical and regulatory milestones provide a second inflection point: the company advanced HALO Clarity trial planning in April 2026, pursued Alzheimer’s FDA engagement, completed a neurostimulation protocol trial in June, and announced a U.S. patent covering its Dynamic Frequency Stimulation approach. With fewer than 10 employees disclosed and no hiring expansion reported, growth appears driven primarily by product, clinical, partnership, and capital-market milestones rather than visible headcount scaling.